Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE